| WB | 1/500 - 1/2000 | Human,Mouse,Monkey |
| IF | 咨询技术 | Human,Mouse,Monkey |
| IHC | 1/200 - 1/1000 | Human,Mouse,Monkey |
| ICC | 技术咨询 | Human,Mouse,Monkey |
| FCM | 1/200 - 1/400 | Human,Mouse,Monkey |
| Elisa | 1/10000 | Human,Mouse,Monkey |
| Aliases | FLJ36605; VIM |
| Entrez GeneID | 7431 |
| clone | 9E7E7 |
| WB Predicted band size | 54kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | Purified recombinant fragment of Vimentin expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是3篇关于Vimentin抗体的参考文献，涵盖其在不同研究中的应用：
---
1. **文献名称**: *Vimentin filaments guide migrating astrocytes towards the wound edge in vivo*
**作者**: Pekny, M., et al.
**摘要**: 该研究利用Vimentin抗体通过免疫荧光技术，发现星形胶质细胞的迁移能力依赖于Vimentin中间丝。在脑损伤模型中，Vimentin缺失导致细胞定向迁移受损，揭示了其在创伤修复中的作用。
---
2. **文献名称**: *Epithelial-mesenchymal transitions in development and disease*
**作者**: Thiery, J.P., et al.
**摘要**: 这篇综述讨论了上皮-间质转化(EMT)的分子机制，其中Vimentin抗体被用于Western blot和免疫组化，作为间质细胞标志物，验证EMT过程中细胞表型转变。
---
3. **文献名称**: *Vimentin in cancer and its potential as a molecular target for cancer therapy*
**作者**: Satelli, A., & Li, S.
**摘要**: 研究通过Vimentin抗体分析多种癌症样本，发现其高表达与转移和不良预后相关，并探讨靶向Vimentin的治疗策略，如在循环肿瘤细胞(CTCs)检测中的应用。
---
**备注**：以上文献均发表于高影响力期刊(如*Cell*、*Nature Reviews Cancer*等)，建议通过PubMed或期刊官网获取全文以验证实验细节。若需具体实验方法，可关注文献的"Materials and Methods"部分。
Vimentin is a type III intermediate filament protein predominantly expressed in mesenchymal cells, playing a critical role in maintaining cell integrity, organelle anchoring, and facilitating cell migration. As a marker of mesenchymal differentiation, vimentin is widely present in fibroblasts, endothelial cells, and immune cells, and its expression is dynamically regulated during development, wound healing, and epithelial-to-mesenchymal transition (EMT). Vimentin antibodies are essential tools in research and diagnostics, enabling the identification of cells undergoing EMT—a process linked to cancer metastasis and fibrosis. These antibodies are also used to study cytoskeletal reorganization in response to stress, infection, or inflammation.
In pathology, vimentin antibodies help distinguish sarcomas (vimentin-positive) from carcinomas (typically vimentin-negative), aiding in tumor classification. They are routinely employed in immunohistochemistry (IHC), immunofluorescence (IF), and Western blot (WB) to validate protein expression in diverse samples. Commercially available vimentin antibodies include monoclonal and polyclonal variants, each optimized for specific applications. Recent studies highlight vimentin's involvement in autoimmune diseases, neurodegenerative disorders, and viral infections, expanding its relevance beyond cancer. However, cross-reactivity with other intermediate filaments requires careful validation to ensure specificity. Overall, vimentin antibodies remain indispensable for exploring cellular dynamics and disease mechanisms.
×
